CASE REPORT {#s1}
===========

A 61-year-old man presented with fever, left knee swelling and pain, and petechial rash on his left leg for 2 months. He had a history of well controlled type 2 diabetes mellitus, peripheral artery disease with bare metal stenting of the left common iliac artery 2 years ago, right hallux and left first metatarsal osteomyelitis requiring amputation, and intravenous drug use (heroin mixed with tap water). On admission, his temperature was 101.6°F. There was a petechial rash on his left leg and left knee effusion with warmth and tenderness ([Image 1A](#I1){ref-type="fig"}). Human immunodeficiency virus, hepatitis C, and interferon-gamma release assay tests were negative.

![Left lower extremity petechial rash before treatment (A) and at 8 weeks after stent removal (B).](ofy20701){#I1}

Blood cultures were positive for acid-fast bacilli on the sixth day of incubation and subsequently identified as *Mycobacterium abscessus*. Left leg skin biopsy and left knee synovial fluid culture also grew *M abscessus*. Transesophageal echocardiogram revealed a 0.3 × 0.3-cm mitral valve vegetation. Abdominal computed tomography (CT) angiogram showed a large pseudoaneurysm adjacent to the left external iliac artery ([Figure 1](#F1){ref-type="fig"}). He continued to be persistently bacteremic, and he subsequently underwent aortoiliac bypass with saphenous vein grafting and stent removal. Cultures from the explanted stent and pseudoaneurysm grew *M abscessus*.

![Computed tomography angiogram shows a 3.3 × 3.5 × 3.3-cm pseudoaneurysm (arrow) adjacent to the left external iliac artergy.](ofy20702){#F1}

*Mycobacterium abscessus* isolates revealed susceptibilities to amikacin (minimum inhibitory concentration \[MIC\], 16.0 µg/mL) and linezolid (2.0 µg/mL), intermediate resistance to cefoxitin (32.0 µg/mL), and resistance to clarithromycin (\>16.0 µg/mL), ciprofloxacin (\>4 µg/mL), doxycycline (\>16.0 µg/mL), moxifloxacin (4.0 µg/mL), imipenem (32 µg/mL), and trimethoprim/sulfamethoxazole (8/125 µg/mL); tigecycline MIC was 0.12 µg/mL.

He was treated with 15 mg/kg amikacin per day and 600 mg of linezolid twice daily for 6 months. His rash resolved ([Image 1B](#I1){ref-type="fig"}). After stent removal, all blood cultures remained negative. Repeat transthoracic echocardiogram showed a normal mitral valve. Fifteen months after diagnosis, he remains clinically stable without any signs of recurrence.

Patient Consent and Confidentiality {#s2}
-----------------------------------

The patient's written consent was obtained prior to the inclusion of photographs and radiographic images. These illustrations have been anonymized.

DISCUSSION {#s3}
==========

Disseminated *M abscessus* disease is rare \[[@CIT0001]\] and carries a high mortality rate \[[@CIT0004]\]. *Mycobacterium abscessus* has been associated with various foreign body infections, including central venous catheters \[[@CIT0004]\], prosthetic heart valves \[[@CIT0008]\], and implanted pacemakers \[[@CIT0009]\]. We highlight a unique case of disseminated disease from an infected endovascular stent. Becasuse *M abscessus* is ubiquitous in soil and water, our patient's infection was likely seeded by intravenous drug use involving tap water injection.

A review of reported endovascular graft-associated *M abscessus* cases \[[@CIT0001]\] shows similar clinical characteristics ([Table 1](#T1){ref-type="table"}), including a localizing rash or erythema ipsilateral to the infected vessel. Most cases presented 1 year or later after graft or stent placement. Bacteremia was evident within 7 to 10 days of presentation, which is typical of rapidly growing mycobacteria. Positron emission tomography-CT proved useful in confirming graft or stent infection in instances in which CT or Doppler ultrasonography did not.

###### 

Clinical Characteristics of Patients With Reported Mycobacterium *abscessus* Endovascular Infection

  Reference                     Age/Sex   Comorbidities       Symptoms                 Site of Infection    Time to Presentation   Imaging Modality   Surgical Treatment   Abx     Duration of Therapy   Bacteremia Clearance   Outcome
  ----------------------------- --------- ------------------- ------------------------ -------------------- ---------------------- ------------------ -------------------- ------- --------------------- ---------------------- ----------
  Marion et al \[[@CIT0001]\]   75/F      DM, CKD             Fever, LLE rash          Left fem-pop         5 months               PET-CT             Y                    C/M     12 months             Y                      Improved
  Kang et al \[[@CIT0002]\]     79/M      DM, CKD, dementia   RUE erythema/ swelling   Right brach-ax       1 year                 DUS                Y                    C/I     8 weeks               Y                      Death
  Umer et al \[[@CIT0003]\]     69/M      CAD, MS             Fever, RLE rash          Right-left fem-fem   2.5 years              PET-CT             Y                    A/I/T   14 weeks              Y                      Improved
  Present case                  61/M      DM, IVDU            Fever, LLE rash          Left CIA stent       2 years                CT                 Y                    A/L     6 months              Y                      Improved

Abbreviations: A, amikacin; Abx, antibiotics; brach-ax, brachial-axillary arteriovenous graft; C, clarithromycin; CAD, coronary artery disease; CIA, common iliac artery; CKD, chronic kidney disease; CT, computed tomography; DM, diabetes mellitus; DUS, doppler ultrasonography; fem-fem, femoral-femoral graft; fem-pop, femoral-popliteal graft; I, imipenem; IVDU, intravenous drug use; L, linezolid; LLE, left lower extremity; M, minocycline; MS, multiple sclerosis; PET, positron emission tomography; RLE, right lower extremity; RUE, right upper extremity; T, tigecycline; Y, yes.

Widespread resistance to most antimicrobials is characteristic of *M abscessus*, making these infections challenging to treat \[[@CIT0006], [@CIT0010]\]. Amikacin appears to be the most active antimicrobial agent against *M abscessus*, with overall resistance rates of 7.7%, followed by clarithromycin (13.9%) and cefoxitin (15.1%) \[[@CIT0010]\]. Intrinsic mechanisms of resistance include efflux pumps, antibiotic-inactivating enzymes, and genetic polymorphisms of antibiotic target genes \[[@CIT0011]\]. Some *M abscessus* subspecies (particularly subspecies *abscessus*) have an active inducible macrolide resistance (*erm*) gene, leading to in vivo resistance to macrolides despite initial in vitro susceptibility \[[@CIT0007], [@CIT0012]\], and have been associated with a higher mortality rate \[[@CIT0007]\]. Thus, all clinically significant *M abscessus* isolates should undergo inducible macrolide resistance testing.

Optimal treatment for disseminated *M abscessus* infections is not well defined. Most experts recommend initial combination antimicrobial therapy with 2--3 active agents, preferably including amikacin \[[@CIT0006], [@CIT0010], [@CIT0013], [@CIT0014]\]. Some experts recommend transitioning initial combination therapy to oral active agents after 8--12 weeks, depending on susceptibilities, extent of disease, and antibiotic tolerability \[[@CIT0014]\]. Treatment duration for disseminated disease is generally recommended for at least 6--12 months \[[@CIT0008], [@CIT0014]\]. Close monitoring for antibiotic-associated toxicities is required, presenting another challenge in treating these infections.

Surgical removal of foreign bodies, such as endovascular grafts, and debridement of infected foci are essential for cure \[[@CIT0006], [@CIT0009], [@CIT0010]\]. *Mycobacterium abscessus*, more than any other rapidly growing mycobacteria, readily adheres to catheter surfaces via biofilm formation \[[@CIT0005]\]. As our case and others have demonstrated ([Table 1](#T1){ref-type="table"}), successful clearance of *M abscessus* bacteremia occurred after graft or stent removal and prolonged antibiotics \[[@CIT0001]\].

CONCLUSIONS {#s4}
===========

Although it is a rare cause of endovascular infection, *Mycobacterium abscessus* can be a highly virulent mycobacteria with the potential to cause life-threatening, disseminated disease. This multidrug-resistant pathogen requires aggressive management, including prompt surgical intervention and prolonged combination antimicrobial therapy.
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